You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. High-Throughput Assay for Profiling Alternative Splicing and Splicing Regulators

    SBC: Biospyder Technologies, Inc.            Topic: 172

    SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users

    SBC: AUTOMATE SCIENTIFIC, INC.            Topic: NIDA

    Abstract E cigarettes (E-cigs) are increasingly popular worldwide, in particular, among youths. E-cigs may contribute to nicotine addiction and are unlikely to discourage conventional cigarette smoking. Mainstream and second-hand E-cig aerosols contain, in addition to nicotine, detectable levels of toxins including carcinogens and heavy metals such as formaldehyde, benzene, nitrosamines, cadmium a ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Noregen(TM), a regenerative medicine ocular therapeutic

    SBC: Retinal Solutions LLC            Topic: NEI

    Project Summary Diabetic retinopathy and Retinal Vein OcclusionRVOaccount for most new cases of blindness in the United StatesThese diseases are marked by retinal swellingedemaand new leaky vessel formationneovascularizationtriggered by pathologically high concentrations of Vascular Endothelial Growth FactorVEGFThe primary treatment is VEGF blocking drugs to control the neovascularization and edem ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Clinical validation and commercialization of a novel hydrogel-based vaginal packing system for pelvic brachytherapy

    SBC: BrachyFoam, LLC            Topic: 102

    This proposal aims to complete preclinical validation and commercialize a novel vaginal packing product based upon a biocompatible polymer hydrogel strategy. The hydrogel will form in situ after being injected into a bag placed within the vaginal cavity during pelvic brachytherapy. The hydrogel packing can then be removed readily after the brachytherapy treatment. This Phase II proposal focuses on ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. The first commercial rapid diagnostic test to detect Paragonimus infections

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Abstract We propose an ultrasensitive rapid diagnostic testRDTto detect exposure to pulmonary flukes of the genus ParagonimusParagonimiasis affects an estimatedmi l l ion people and remains amongst the most neglected of all neglected tropical diseasesNTDsThis trematode is acquired upon ingestion of raw or undercooked freshwater crustaceans and migrates to the lungs where it forms cystsTreatment is ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting lipid rafts for treatment of asthma

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIAID

    PROJECT SUMMARY Asthma, characterized by airways obstruction with symptoms of wheezing, shortness of breath, chest tightness and consequently cough, remains a significant health problem. While advances in bronchodilator, corticosteroid and Th2-targeting therapy allow for well-controlled asthma in a large population of patients, subjects with severe, corticosteroid resistant asthma require frequent ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer

    SBC: BIOVINC, LLC            Topic: 102

    ABSTRACTBreast CancerBCis the leading cause of cancer death for woman in the USBreast cancer is treated by a combination of surgeryradiationand various types of chemo and targeted therapeutic strategiesApproximately half of patients who have positive sentinel lymph nodes at surgeryand as many asof patients who do noteventually present with metastatic diseaseOverof BC patients eventually have skele ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting lipid rafts for treatment of migraine

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NINDS

    PROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government